-
Product Insights
New![]()
Net Present Value Model: Daiichi Sankyo Co Ltd’s Raludotatug Deruxtecan
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Daiichi Sankyo Co Ltd’s Patritumab deruxtecan
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Daiichi Sankyo Co Ltd’s Ifinatamab Deruxtecan
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Daiichi Sankyo Co Ltd’s Datopotamab deruxtecan
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Daiichi Sankyo Co Ltd’s DS-6000
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Mitsubishi – Minato-Ku Daiichi Tamachi Building Redevelopment – Tokyo
Equip yourself with the essential tools needed to make informed and profitable decisions with our Mitsubishi - Minato-Ku Daiichi Tamachi Building Redevelopment - Tokyo report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Daiichi Kotsu – Grand Palace Shimizu Condominium Tower – Fukuoka
Equip yourself with the essential tools needed to make informed and profitable decisions with our Daiichi Kotsu - Grand Palace Shimizu Condominium Tower - Fukuoka report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
New![]()
Net Present Value Model: Cytokinetics Inc’s Aficamten
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: AstraZeneca Plc’s Tozorakimab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: GSK plc’s Latozinemab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Nuvation Bio Inc’s NUV-868
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Daiichi Sankyo Co Ltd – Company Profile
Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Hepenofovir fumarate in Hepatitis B
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Hepenofovir fumarate in Hepatitis B Drug Details: Hepenofovir fumarate is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Clotrimazole in Otitis Externa
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Clotrimazole in Otitis ExternaDrug Details:clotrimazole (SVT-15652) is under development for the treatment of fungal otitis externa...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-1211 in Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.DS-1211 in Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome)Drug Details:DS-1211 is under development for the prevention...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-65 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMM-65 in Ovarian Cancer Drug Details:IMM-65 is under development for the treatment of solid tumors including,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NNC0487-0111 in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NNC0487-0111 in Obesity Drug Details: NNC0487-0111 is under development for the treatment of overweight...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-9606a in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DS-9606a in Solid Tumor Drug Details:DS-9606a is under development for the treatment of solid tumors. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-9606a in Uterine Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DS-9606a in Uterine Cancer Drug Details:DS-9606a is under development for the treatment of solid tumors. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-9606a in Metastatic Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DS-9606a in Metastatic Ovarian Cancer Drug Details:DS-9606a is under development for the treatment of solid tumors....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.